Andrew J. Prongay, Ph.D.

*** ****** ***

Harleysville, PA 19438

acc71h@r.postjobfree.com

Cell: 908-***-****

Home: 267-***-****

Summary

Protein Scientist with extensive experience in molecular biology and

protein chemistry (protein expression, protein purification, protein

characterization and analysis). Diverse experience includes working on

Structure Based Drug Design projects. Key member of the team that

designed the HCV NS34A protease inhibitor compound that became the drug

Victrelis. Strengths include coaching and training, experimental

creativity, data analysis and delivering information in a timely manner to

assist the efforts of team members in moving projects forward.

Technical Expertise

Generated expression construct and site-direct mutations for protein

production in bacterial, and insect cells. A limited experience with

mammalian cells. Succeeded in the expression, purification, refolding,

characterization and crystallization of more than 25 proteins of 1 mg to

700 mg scales. Technical skills include construct design, cloning, PCR,

qPCR, DNA sequencing, site-directed mutagenesis, operation of 15 - 200 L

Bioreactors, conventional and affinity liquid chromatography (IMAC, IEC,

SEC, RP, HIC, Chromatofocusing) using AKTA (Unicorn software), FPLC, HPLC

and UPLC (including Acquity H-Class Bio systems and Empower software),

electrophoresis (SDS-PAGE, isoelectric focusing, native gels, Western

blots), enzymology, enzyme assays, ligand binding measurements via TdF,

TdCD, BIAcore (SPR), ELISA, spectroscopy (UV/VIS, CD, Fluorescence),

Light Scattering (Static and Dynamic), X-ray diffraction data collection

and processing, structure determination, compound building and modeling,

lead optimization via structure based drug design, mass spectrometry (LC-MS

and LC-MS-MS) of intact proteins and peptides, peptide mapping. I have

also performed chemical modifications of proteins and thiol titrations. I

have a good understanding of ITC and DSC calorimetric methods.

Supervisory Experience

Supervised and provided extensive training of up to four scientists

concurrently with skills ranging from summer interns and recent graduates

at the technical associate level up to and including Ph.D. Principal

Scientists.

Professional Experience

AGILE-1/ALLSOURCE PPS, contract to MERCK MANUFACTURING DIVISION, Elkton, VA

2013

Senior Analytics Specialist, Technical Operation

Perform analytics in support of the manufacturing of biologics as part of

Technical Operations, including enzyme assays, ELISA assays, reagent

quantitation assays, qPCR for Residual DNA quantitation and plasmid copy

number determination, HPLC/UPLC assays of protein samples and degradation

analysis, protein quantitation assays, drafting SOPs, performing cGMP

validation assays in Quality Operations.

UNEMPLOYED and PURSUING NEW OPPORTUNITIES, 2012

Laid-off as part of a downsizing and outsourcing process following the

merger of Schering-Plough and Merck.

merck research laboratories, West Point, PA 2010-2011

Principal Scientist, Protein Science

(Relocation and position change due to the merger of Merck and Schering-

Plough.)

Supervised group of four scientists in Protein Science Department of Merck

Research Laboratories focused on generating expression constructs and

preparing proteins for ALIS screening, BioNMR and X-ray Crystallography.

Schering-Plough research Institute, Kenilworth, NJ and Cambridge, MA

1993-2010

Principal Scientist, Structural Chemistry/Protein Science, (2003-2010)

Some Key Technical Achievements:

HCV NS2 Protease:

. Designed constructs for the expression of a C-terminally truncated HCV

Genotype 2A NS2 Protease in E. coli

. Expressed, purified and refolded one of the HCV Genotype 2A NS2 Protease

constructs for ALIS screening.

. Demonstrated trans-cleavage of peptides having sequence spanning the P3

through P'6 sequence via LCMS and LC- MS-MS.

AKT3 Catalytic Domain:

. Supported drug discovery efforts with expression, purification,

characterization and crystallization of AKT3 catalytic domain. Solved

the three dimensional X-ray structure of AKT3 catalytic domain at better

than 2.0A resolution. Provided structural information on approximately

50 compounds (inhibitors) bound to AKT3 catalytic domain

HIV Integrase:

. Generated doubly and triply mutated constructs of catalytic domain and

full-length HIV Integrase, respectively.

. Expressed, purified, and characterized both constructs and crystallized

the catalytic domain construct.

. Prepared stable ternary complexes of both constructs with

oligonucleotides and inhibitors and characterized these by SEC, TdCD, TdF

and Light Scattering.

. Submitted binary complexes (Integrase and oligonucleotides) for ALIS

screening.

. Bioreactors:

. Contributed to layout design of a bacterial BioReactor Fermentation Room.

Coordinated the establishment of functional SOPs for the operation of the

BioLaffite BioReactors for high cell density growth and protein

expression.

Associate Principal Scientist, Structural Chemistry/Protein Science,

(1998-2003)

Some Key Technical Achievements:

HCV NS3-4A Protease

. Supported the drug discovery efforts of the synthetic chemistry group by

purifying and crystallizing the NS3 protease in complex with an NS4A

peptide, and by providing structural information on approximately 200

compounds (inhibitors and product analogs) bound to the HCV NS3 protease

domain.

. Key member of the team that designed Victrelis (Boceprevir/SCH503034) and

the back-up compound Narlaprevir.

Senior Scientist, Structural Chemistry/Protein Science, (1993-1998)

Some Key Technical Achievements:

IL5R:

. Purified shIL5R? and separated the isoelectric forms.

. Characterized the biochemical and biophysical properties of the shIL5R?.

. Crystallized the shIL5R? complexed with deglycosylated hIL5.

. Developed a screening assay based on the surface plasmon resonance

technology using the BIAcore.

Grb2:

. Purified the Grb2 SH2 domain, separated the intact domain from

proteolyzed fragments.

. Crystallized the Grb2 SH2 domain.

CMV Protease:

. Generated site-directed mutations of CMV protease replacing four of the

five cysteines with alanines (designated Quad3).

. Generated expression constructs of the mutated CMV protease.

. Purified the Quad3 protein.

. Chemically modified the Quad3 at Cys161 with two different mercury

compounds.

. Crystallized the derivatized and underivatized Quad3.

. Inducible Nitric Oxide Synthase.

. Identified conditions for the crystallization of human iNOS arginine

binding domain fragment using MgSO4 as a precipitant. This facilitated

the structure determination by X-ray crystallography.

. Performed spectroscopic analyses of iNOS binding to inhibitor compounds.

AWARDS

. Received the President's Award for Discovery "for Outstanding Scientific

and Technical Achievement in Discovery of an Orally Bioavailable NS3

Protease Inhibitor for Treatment of Hepatitis C Infections through

Structure Assisted Design", Schering-Plough Research Institute.

. Received the President's Award for Discovery "for Outstanding Scientific

and Technical Achievement in Protein Structures of Inducible and

Constitutive Human NO Synthases: Driving the Search for Selective

Inhibitors", Schering-Plough Research Institute.

. Received several Excellence Awards and Shining Performance Awards,

Schering-Plough Research Institute.

Education and Academic Research Experience

Purdue University, West Lafayette, IN

Post-Doctoral Research Associate, Department of Biological Sciences

(Advisor: Dr. Michael G. Rossmann)

Scholar of the American Foundation for AIDS Research, Los Angeles, CA

University of Michigan, Ann Arbor, MI

Ph.D. (Biological Chemistry) University of Michigan, Ann Arbor, MI

Thesis: Characterization of Two Active Site Mutants of Thioredoxin

Reductase from Escherichia coli.

Research Advisor: Dr. Charles H. Williams, Jr.

Dominic D. Dziewiatkowski Award in recognition of an Outstanding Ph.D.

Thesis Department of Biological Chemistry, University of Michigan

M.S., Biological Chemistry

Graduate Student Research Assistant, Department of Biological Chemistry

(Advisor: Dr. Charles H. Williams, Jr.)

Rutgers the State University of New Jersey. New Brunswick, NJ

B.S., Biology

Undergraduate Research Assistant (Advisor: Dr. Harry Brown)

Cook College, Rutgers University

Received the Joe M. Hopping Award for "Outstanding performance in

chemistry and overall educational and social excellence." Department of

Chemistry, Central Missouri State University, where I started my

undergraduate education while I was still in the United States Air Force.

Military Experience

Medical Service Specialist, United States Air Force

Performed primary emergency medical care. Honorably discharged with a rank

of Staff Sergeant, E-5.

. Receive a "Below the Zone Promotion", United States Air Force

. Selected as Hospital Outstanding Airman of the Quarter (Jan-Mar.),

United States Air Force

Patents & Pac Recommendations

1. Patent Case JB06807L01US: Factor IXa Crystals, Related Complexes and

Methods. B.M. Beyer, A.W. Hruza, R.N. Ingram, V.S. Madison, A.J. Prongay,

P. Reichert (filed on 5/7/2009, Issued 2011).

2. Patent Case JB06809L01US: Assay for PCSK9 Inhibitors. B.M. Beyer, T.

Hesson, H.V. Le, A.J. Prongay, K. Kalghatgi, J.J. Gesell, R. N. Ingram,

M.R. Ziebell (filed on 6/30/2008, issued as US 8206943 on 6/26/2012)

3. Patent Case JB06219US01: Kinase Domain polypeptide of human protein

kinase B gamma (AKT3) A.J. Prongay, T.O. Fischmann, C. Kumar, V.S.

Madison, J.E. Myers, P. Reichert, R. Syto, W.T. Windsor, L. Xiao, T. W.

Mayhood (filed 8/30/2007, issued as US 8088611 on 1/3/2012)

4. Patent Case: Kinase Inhibitors. T.Y. Chan, B.A. McKittrick, H. Pu, L.

Hong, A.J. Prongay, L. Xiao, M.A. McCoy (filed 3/28,2007; issued US

2008/0021019 A1 on 1/24/2008).

5. Patent Case: Kinase Inhibitors. T.Y. Chan, T.O. Fischmann, M.A. McCoy,

B.A. McKittrick, A.J. Prongay, H. Pu, L. Wang, L. Xiao (filed 1/24/2006,

issued as US 2008/0004257 A1).

6. Patent Case IN01154P: Macrocyclic NS-3-Serine Protease Inhibitors of

Hepatitis C Virus Comprising N-Cyclic P2 Moieties. K. X. Chen, A.

Arrasappan, S. Venkatraman, T. Parekh, H. Gu, F. G. Njoroge, V. M.

Girijavallabhan, A. K. Ganguly, A. Saksena, E. Jao, N. H. Yao, A. J.

Prongay, and V. S. Madison (filed 4/3/2001, issued as US 6,846,802 B2 on

7/25/2005).

7. Patent Case IN01155K: Macrocyclic NS-3-Serine Protease Inhibitors of

Hepatitis C Virus Comprising Alkyl and Aryl Alanine P2 Moieties. S.

Venkatraman, K. X. Chen, A. Arrasappan, F. G. Njoroge, V. M.

Girijavallabhan, A. K. Ganguly, T. Y. Chan, B. A. McKittrick, N. H. Yao,

A. J. Prongay, and V. S. Madison (filed 4/17/2001, issued as US 6,914,122

B2 on 7/5/2005).

8. Recommendation of SCH503034 (Boceprevir) for Development. HCV Protease

Project Team.

(Recommendation Submitted in 2001). This resulted in the drug Victrelis.

9. Recommendation of SCH900512 (Narlaprevir) for Development. HCV Protease

Project Team

Publications

1. 2012: Venkatraman, S.; Prongay, A.J., and Njoroge, F.G. Discovery of

Boceprevir and Narlaprevir. A case study for role of structure based drug

design. (submitted to J. Med. Chem. as an Invited Review article for ABDD

III).

2. 2010: Tong X; Arasappan A; Bennett F; Chase R; Feld B; Guo Z; Hart A;

Madison V; Malcolm B; Pichardo J; Prongay A; Ralston R; Skelton A; Xia E;

Zhang R; Njoroge F G. Preclinical characterization of the antiviral

activity of SCH 900518 (Narlaprevir), a novel mechanism-based inhibitor

of hepatitis C virus NS3 protease. Antimicrobial agents and

chemotherapy 2010;54(6):2365-70.

3. 2010: Bennett F.; Huang Y.; Hendrata S.; Lovey R.; Bogen S. L; Pan W.;

Guo Z.; Prongay A.; Chen K. X; Arasappan A.; Venkatraman S.; Velazquez

F.; Nair L.; Sannigrahi M.; Tong X.; Pichardo J.; Cheng K.-C.;

Girijavallabhan V.M; Saksena A.K; Njoroge F.G. The introduction of P4

substituted 1-methylcyclohexyl groups into Boceprevir: a change in

direction in the search for a second generation HCV NS3 protease

inhibitor. Bioorganic & medicinal chemistry letters 2010;20(8):2617-21.

4. 2010: Nair L.G; Sannigrahi M.; Bogen S.; Pinto P.; Chen K.X; Prongay A.;

Tong X.; Cheng K-C; Girijavallabhan V.; Njoroge F.G. P4 capped amides and

lactams as HCV NS3 protease inhibitors with improved potency and DMPK

profile. Bioorganic & medicinal chemistry letters 2010;20(2):567-70.

5. 2009: Sheth P.R; Basso A.; Duca J.S; Lesburg C.A; Ogas P.; Gray K.; Nale

L.; Mannarino A.F; Prongay A.J; Le H.V. Thermodynamics of nucleotide and

inhibitor binding to wild-type and ispinesib-resistant forms of human

kinesin spindle protein. Biochemistry 2009;48(46):11045-55.

6. 2009: Venkatraman S.; Blackman M.; Wu W.; Nair L.; Arasappan A.; Padilla

A.; Bogen S.; Bennett F.; Chen K.; Pichardo J.; Tong X.; Prongay A.;

Cheng K.-C.; Girijavallabhan V.; Njoroge FG

Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease.

Inhibitors with improved cellular potencies. Bioorganic & medicinal

chemistry 2009;17(13):4486-95.

7. 2009: Chen K.X; Nair L.; Vibulbhan B.; Yang W.; Arasappan A.; Bogen S.L;

Venkatraman S.; Bennett F.; Pan W.; Blackman M.L; Padilla A.I; Prongay

A.; Cheng K.-C.; Tong X,; Shih N.-Y.; Njoroge F G.

Second-generation highly potent and selective inhibitors of the hepatitis

C virus NS3 serine protease.

Journal of medicinal chemistry 2009;52(5):1370-9.

8. 2009: Venkatraman S.; Velazquez F.; Wu W.; Blackman M.; Chen KX; Bogen

S.; Nair L.; Tong X.; Chase R.; Hart A.; Agrawal S.; Pichardo J.; Prongay

A.; Cheng K.-C.; Girijavallabhan V.; Piwinski J.; Shih NY.; Njoroge F.G.

Discovery and structure-activity relationship of P1-P3 ketoamide derived

macrocyclic inhibitors of hepatitis C virus NS3 protease. Journal of

medicinal chemistry 2009;52(2):336-46.

9. 2009: Venkatraman S.; Wu W.; Prongay A.; Girijavallabhan V.; Njoroge F.G

Potent inhibitors of HCV-NS3 protease derived from boronic acids.

Bioorganic & medicinal chemistry letters 2009;19(1):180-3.

10. 2008: Hou Y.; McGuinness DE; Prongay AJ; Feld B.; Ingravallo P.; Ogert

RA; Lunn CA; Howe J. A

Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75

interaction using the AlphaScreen luminescent proximity assay. Journal of

biomolecular screening: the official journal of the Society for

Biomolecular Screening 2008;13(5):406-14.

11. 2008: Madison V; Prongay AJ; Guo Z; Yao N; Pichardo J; Fischmann T;

Strickland C; Myers J; Weber PC; Beyer BM; Ingram R; Hong Z; Prosise WW;

Ramanathan L; Taremi SS; Yarosh-Tomaine T; Zhang R; Senior M; Yang RS;

Malcolm B; Arasappan A; Bennett F; Bogen SL; Chen K; Jao E; Liu YT; Lovey

RG; Saksena AK; Venkatraman S; Girijavallabhan V; Njoroge FG Key steps

in the structure-based optimization of the hepatitis C virus NS3/4A

protease inhibitor SCH503034. Journal of synchrotron

radiation 2008;15(Pt 3):204-7.

12. 2008: Tong X; Bogen S; Chase R; Girijavallabhan V; Guo Z; Njoroge FG;

Prongay A; Saksena Al; Skelton A; Xia E; Ralston R Characterization of

resistance mutations against HCV ketoamide protease inhibitors.

Antiviral research 2008;77(3):177-85.

13. 2007: Vel zquez F; Venkatraman S; Wu W; Blackman M; Prongay A;

Girijavallabhan V; Shih N-Y; Njoroge FG Application of ring-closing

metathesis for the synthesis of macrocyclic peptidomimetics as inhibitors

of HCV NS3 protease. Organic letters 2007;9(16):3061-4.

14. 2007: Prongay AJ; Guo Z; Yao N; Pichardo J; Fischmann T; Strickland C;

Myers J; Weber PC; Beyer BM; Ingram R; Hong Z; Prosise WW; Ramanathan L;

Taremi SS; Yarosh-Tomaine T; Zhang R; Senior M; Yang R-S; Malcolm B;

Arasappan A; Bennett F; Bogen SL; Chen K; Jao E; Liu Y-T; Lovey RG;

Saksena AK; Venkatraman S; Girijavallabhan V; Njoroge FG; Madison V

Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-

(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S 1,1-

dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-

dimethyl-3-azabicyclo[3.1.0] hexan-2(S)-carboxamide (Sch 503034) II. Key

steps in structure-based optimization. Journal of medicinal

chemistry 2007;50(10):2310-8.

15. 2007: Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R;

Agrawal S; Bogen S; Saksena A; Cheng K-C; Prongay A; Njoroge FG; Baroudy

BM; Negro F In vitro antiviral activity of SCH446211 (SCH6), a novel

inhibitor of the hepatitis C virus NS3 serine protease. The Journal of

antimicrobial chemotherapy 2007;59(1):51-8.

16. 2006: Venkatraman S; Bogen SL; Arasappan A; Bennett F; Chen K; Jao E;

Liu Y-T; Lovey R; Hendrata S; Huang Y; Pan W; Parekh T; Pinto P; Popov V;

Pike R; Ruan S; Santhanam B; Vibulbhan B; Wu W; Yang W; Kong J; Liang X;

Wong J; Liu R; Butkiewicz N; Chase R; Hart A; Agrawal S; Ingravallo P;

Pichardo J; Kong R; Baroudy B; Malcolm B; Guo Z; Prongay A; Madison V;

Broske L; Cui X; Cheng K-C; Hsieh Y; Brisson J-M; Prelusky D; Korfmacher

W; White R; Bogdanowich-Knipp S; Pavlovsky A; Bradley P; Saksena AK;

Ganguly A; Piwinski J; Girijavallabhan V; Njoroge FG Discovery of (1R,5S)-

N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S 1,1-

dimethylethyl) amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-

dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a

selective, potent, orally bioavailable hepatitis C virus NS3 protease

inhibitor: a potential therapeutic agent for the treatment of hepatitis C

infection. Journal of medicinal chemistry 2006;49(20):6074-86.

17. 2006: Arasappan A; Njoroge FG; Chen KX; Venkatraman S; Parekh TN; Gu H;

Pichardo J; Butkiewicz N; Prongay A; Madison V; Girijavallabhan V P2-P4

macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.

Bioorganic & medicinal chemistry letters 2006;16(15):3960-5.

18. 2006: Bogen SL; Arasappan A; Bennett F; Chen K; Jao E; Liu Y-T; Lovey

RG; Venkatraman S; Pan W; Parekh T; Pike RE; Ruan S; Liu R; Baroudy B;

Agrawal S; Chase R; Ingravallo P; Pichardo J; Prongay A; Brisson J-M;

Hsieh TY; Cheng K-C; Kemp SJ; Levy OE; Lim-Wilby M; Tamura SY; Saksena

AK; Girijavallabhan V; Njoroge FG Discovery of SCH446211 (SCH6): a new

ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA

replication. Journal of medicinal chemistry 2006;49(9):2750-7.

19. 2006: Malcolm BA; Liu R; Lahser F; Agrawal S; Belanger B; Butkiewicz N;

Chase R; Gheyas F; Hart A; Hesk D; Ingravallo P; Jiang C; Kong R; Lu J;

Pichardo J; Prongay A; Skelton A; Tong X; Venkatraman S; Xia E;

Girijavallabhan V; Njoroge F G SCH 503034, a mechanism-based inhibitor

of hepatitis C virus NS3 protease, suppresses polyprotein maturation and

enhances the antiviral activity of alpha interferon in replicon cells.

Antimicrobial agents and chemotherapy 2006;50(3):1013-20.

20. 2006: Venkatraman S; Njoroge FG; Wu W; Girijavallabhan V; Prongay AJ;

Butkiewicz N; Pichardo J

Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-

aza-bicyclo[2.2.1]heptane-3-carboxylic acid. Bioorganic & medicinal

chemistry letters 2006;16(6):1628-32.

21. 2006: Bogen SL; Ruan S; Liu R; Agrawal S; Pichardo J; Prongay A;

Baroudy B; Saksena AK; Girijavallabhan V; Njoroge FG Depeptidization

efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine

protease: effect on HCV replicon activity. Bioorganic & medicinal

chemistry letters 2006; 16(6):1621-7.

22. 2006: Yi MK; Tong X; Skelton A; Chase R; Chen T; Prongay A; Bogen SL;

Saksena AK; Njoroge FG; Veselenak RL; Pyles RB; Bourne N; Malcolm BA;

Lemon SM Mutations conferring resistance to SCH6, a novel hepatitis C

virus NS3/4A protease inhibitor. Reduced RNA replication fitness and

partial rescue by second-site mutations. The Journal of biological

chemistry 2006;281(12):8205-15.

23. 2006: Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B;

Yang W; Parekh TN; Pichardo J; Prongay A; Cheng K-C; Butkiewicz N; Yao N;

Madison V; Girijavallabhan V Novel potent hepatitis C virus NS3 serine

protease inhibitors derived from proline-based macrocycles. Journal of

medicinal chemistry 2006;49(3):995-1005.

24. 2006: Tong X; Guo Z; Wright-Minogue J; Xia E; Prongay A; Madison V; Qiu

P; Venkatraman S; Velazquez F; Njoroge FG; Malcolm BA Impact of

naturally occurring variants of HCV protease on the binding of different

classes of protease inhibitors. Biochemistry 2006;45(5):1353-61.

25. 2006: Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N;

Madison V; Girijavallabhan V Potent 7-hydroxy-1,2,3,4-

tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of

hepatitis C virus NS3 protease. Journal of medicinal

chemistry 2006;49(2):567-74.

26. 2005: Chen KX; Njoroge FG; Vibulbhan B; Prongay A; Pichardo J; Madison

V; Buevich A; Chan T-M

Proline-based macrocyclic inhibitors of the hepatitis C virus:

stereoselective synthesis and biological activity. Angewandte Chemie

(International ed. in English) 2005;44(43):7024-8.

27. 2005: Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N;

Madison V; Girijavallabhan V Design, synthesis, and biological activity

of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of

hepatitis C virus NS3 serine protease. Journal of medicinal

chemistry 2005;48(20):6229-35.

28. 2005: Bogen S; Saksena A K; Arasappan A; Gu H; Njoroge F G;

Girijavallabhan V; Pichardo J; Butkiewicz N; Prongay A; Madison V

Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1

cyclopropyl alanine combination for improved potency. Bioorganic &

medicinal chemistry letters 2005;15(20):4515-9.

29. 2005: Chen KX; Njoroge FG; Prongay A; Pichardo J; Madison V;

Girijavallabhan V Synthesis and biological activity of macrocyclic

inhibitors of hepatitis C virus (HCV) NS3 protease. Bioorganic &

medicinal chemistry letters 2005;15(20):4475-8.

30. 2005: Arasappan A; Njoroge F G; Chan T-Y; Bennett F; Bogen S L; Chen K;

Gu H; Hong L; Jao E; Liu Y-T; Lovey R G; Parekh T; Pike R E; Pinto P;

Santhanam B; Venkatraman S; Vaccaro H; Wang H; Yang X; Zhu Z; Mckittrick

B; Saksena A K; Girijavallabhan V; Pichardo J; Butkiewicz N; Ingram R;

Malcolm B; Prongay A; Yao N; Marten B; Madison V; Kemp S; Levy O; Lim-

Wilby M; Tamura S; Ganguly A K Hepatitis C virus NS3-4A serine protease

inhibitors: SAR of P'2 moiety with improved potency. Bioorganic &

medicinal chemistry letters 2005;15(19):4180-4.

31. 2005: Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao

NH; Prongay AJ; Butkiewicz N; Pichardo J Design and synthesis of

depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using

structure-based drug design. Journal of medicinal

chemistry 2005;48(16):5088-91.

32. 2004: Arasappan A; Njoroge FG; Parekh TN; Yang X; Pichardo J;

Butkiewicz N; Prongay A; Yao N; Girijavallabhan V Novel 2-

oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-

4A serine protease inhibitors: synthesis, activity, and X-ray crystal

structure of an enzyme inhibitor complex. Bioorganic & medicinal

chemistry letters 2004;14(23):5751-5.

33. 2003: Guo Z; Durkin J; Fischmann T; Ingram R; Prongay A; Zhang R;

Madison V

Application of the lambda-dynamics method to evaluate the relative

binding free energies of inhibitors to HCV protease. Journal of medicinal

chemistry 2003;46(25):5360-4.

34. 1999: Fischmann TO; Hruza A; Niu XD; Fossetta JD; Lunn CA; Dolphin E;

Prongay AJ; Reichert P; Lundell DJ; Narula SK; Weber PC Structural

characterization of nitric oxide synthase isoforms reveals striking

active-site conservation. Nature structural biology 1999;6(3):233-42.

35. 1997: McNemar C; Snow ME; Windsor WT; Prongay A; Mui P; Zhang R; Durkin

J; Le HV; Weber PC Thermodynamic and structural analysis of

phosphotyrosine polypeptide binding to Grb2-SH2.

Biochemistry 1997;36(33):10006-14.

36. 1996: Momany C; Kovari LC; Prongay AJ; Keller W; Gitti RK; Lee BM;

Gorbalenya AE; Tong L; McClure J; Ehrlich LS; Summers MF; Carter C;

Rossmann MG Crystal structure of dimeric HIV-1 capsid protein. Nature

structural biology 1996;3(9):763-70.

37. 1992: Prongay AJ; Williams CH Oxidation-reduction properties of

Escherichia coli thioredoxin reductase altered at each active site

cysteine residue. The Journal of biological chemistry 1992; 267(35)

:25181-8.

38. 1990: Prongay AJ; Smith TJ; Rossmann MG; Ehrlich LS; Carter CA; McClure

J Preparation and crystallization of a human immunodeficiency virus p24-

Fab complex. Proceedings of the National Academy of Sciences of the

United States of America 1990;87(24):9980-4.

39. 1990: Prongay AJ; Williams CH Evidence for direct interaction between

cysteine 138 and the flavin in thioredoxin reductase. A study using

flavin analogs. The Journal of biological chemistry 1990; 265(31):18968-

75.

40. 1989: Prongay AJ; Engelke DR; Williams CH Characterization of two

active site mutations of thioredoxin reductase from Escherichia coli.

The Journal of biological chemistry 1989;264(5):2656-64.

41. 1989: Williams CH; Allison N; Russell GC; Prongay AJ; Arscott LD; Datta

S; Sahlman L; Guest JR

Properties of lipoamide dehydrogenase and thioredoxin reductase from

Escherichia coli altered by site-directed mutagenesis. Annals of the New

York Academy of Sciences 1989;573:55-65.

42. 1983: Taskar PK; Prongay A; Chattopadhyay SK; Das YT; Brown HD

Energetics of the oxidase activity of NADPH-cytochrome P-450 reductase.

Cancer biochemistry biophysics 1983;6(4):269-73.

Contact this candidate